Brokers Offer Predictions for SNDX Q3 Earnings

Key Points

• HC Wainwright predicts Syndax Pharmaceuticals will report a Q3 2025 earnings per share of ($0.68), with a current full-year estimate of ($3.72) per share.
• Recent analyst ratings show a mix of sentiments, with two analysts rating it as Strong Buy, while Weiss Ratings holds a Sell rating. The current consensus target price is $38.00.
• Syndax Pharmaceuticals' stock has experienced a 5.0% decline recently, with a market cap of $1.23 billion and a price-to-earnings ratio of -3.68.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Syndax Pharmaceuticals in a research note issued to investors on Wednesday, October 15th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($0.68) for the quarter. HC Wainwright currently has a "Strong-Buy" rating on the stock. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($3.72) per share. HC Wainwright also issued estimates for Syndax Pharmaceuticals' Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($3.05) EPS, Q1 2026 earnings at ($0.50) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.33) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.48) EPS, FY2027 earnings at ($0.60) EPS, FY2028 earnings at $0.38 EPS and FY2029 earnings at $2.08 EPS.

A number of other equities analysts also recently weighed in on the company. UBS Group dropped their target price on Syndax Pharmaceuticals from $37.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, July 15th. The Goldman Sachs Group lifted their target price on shares of Syndax Pharmaceuticals from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Friday, September 5th. B. Riley upgraded shares of Syndax Pharmaceuticals to a "strong-buy" rating in a report on Wednesday, August 6th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Syndax Pharmaceuticals in a report on Wednesday, October 8th. Finally, Stifel Nicolaus initiated coverage on Syndax Pharmaceuticals in a research report on Wednesday, September 10th. They set a "buy" rating and a $44.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $38.00.

Syndax Pharmaceuticals Stock Down 5.0%

NASDAQ:SNDX opened at $14.30 on Monday. The business's fifty day moving average price is $15.52 and its 200 day moving average price is $12.34. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -3.68 and a beta of 0.68. The company has a current ratio of 4.71, a quick ratio of 4.55 and a debt-to-equity ratio of 2.06. Syndax Pharmaceuticals has a 1-year low of $8.58 and a 1-year high of $22.50.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($0.83) EPS for the quarter, topping the consensus estimate of ($1.01) by $0.18. Syndax Pharmaceuticals had a negative net margin of 428.48% and a negative return on equity of 130.47%. The company had revenue of $37.96 million during the quarter, compared to analysts' expectations of $26.64 million. During the same period last year, the company posted ($0.80) earnings per share. The business's revenue for the quarter was up 984.5% on a year-over-year basis.

Insider Transactions at Syndax Pharmaceuticals

In related news, Director Dennis Podlesak sold 19,200 shares of the business's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $15.84, for a total value of $304,128.00. Following the completion of the sale, the director directly owned 191,763 shares in the company, valued at approximately $3,037,525.92. The trade was a 9.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Michael A. Metzger sold 157,307 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $16.41, for a total value of $2,581,407.87. Following the sale, the chief executive officer directly owned 298,661 shares of the company's stock, valued at $4,901,027.01. The trade was a 34.50% decrease in their position. The disclosure for this sale can be found here. Insiders sold 195,707 shares of company stock valued at $3,183,904 in the last ninety days. Insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quarry LP bought a new stake in Syndax Pharmaceuticals during the first quarter valued at about $25,000. Lazard Asset Management LLC bought a new stake in Syndax Pharmaceuticals during the 2nd quarter valued at approximately $66,000. Tower Research Capital LLC TRC grew its holdings in Syndax Pharmaceuticals by 103.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company's stock valued at $79,000 after buying an additional 4,308 shares during the last quarter. Prudential Financial Inc. bought a new position in Syndax Pharmaceuticals in the 2nd quarter worth approximately $97,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Syndax Pharmaceuticals during the second quarter worth approximately $103,000.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.